EWCZ vs LFST

For growth investors, LifeStance Health Group, Inc.

(LFST) is the stronger pick with 13. 9% revenue growth year-over-year, versus -1. 9% for European Wax Center, Inc. (EWCZ). European Wax Center, Inc. (EWCZ) offers the better valuation at 26. 4x trailing P/E (8. 4x forward), making it the more compelling value choice. Analysts rate LifeStance Health Group, Inc. (LFST) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, European Wax Center, Inc.

(EWCZ) is the cheapest at 26. 4x versus LifeStance Health Group, Inc. at 368. 0x. On forward P/E, European Wax Center, Inc. is actually cheaper at 8. 4x.

Over the past 5 years, European Wax Center, Inc.

(EWCZ) delivered a total return of -57. 5%, compared to -66. 4% for LifeStance Health Group, Inc. (LFST). Over 10 years, the gap is even starker: EWCZ returned -57. 5% versus LFST's -66. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), LifeStance Health Group, Inc.

(LFST) is the lower-risk stock at 1. 20β versus European Wax Center, Inc. 's 1. 46β — meaning EWCZ is approximately 22% more volatile than LFST relative to the S&P 500. On balance sheet safety, LifeStance Health Group, Inc. (LFST) carries a lower debt/equity ratio of 13% versus 4% for European Wax Center, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), LifeStance Health Group, Inc.

(LFST) is pulling ahead at 13. 9% versus -1. 9% for European Wax Center, Inc. (EWCZ). On earnings-per-share growth, the picture is similar: LifeStance Health Group, Inc. grew EPS 113. 3% year-over-year, compared to 29. 4% for European Wax Center, Inc.. Over a 3-year CAGR, LFST leads at 18. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

European Wax Center, Inc.

(EWCZ) is the more profitable company, earning 4. 8% net margin versus 0. 7% for LifeStance Health Group, Inc. — meaning it keeps 4. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EWCZ leads at 22. 0% versus 1. 8% for LFST. At the gross margin level — before operating expenses — EWCZ leads at 73. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, European Wax Center, Inc.

(EWCZ) trades at 8. 4x forward P/E versus 100. 7x for LifeStance Health Group, Inc. — 92. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LFST: 26. 4% to $9. 30.

In this comparison, EWCZ (0.

3% yield) pays a dividend. LFST does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, LifeStance Health Group, Inc.

(LFST) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 20)). Both have compounded well over 10 years (LFST: -66. 4%, EWCZ: -57. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EWCZ (Consumer Defensive) and LFST (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.